Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion

British Journal of Cancer

Volumn 88, Issue 2, 2003, Pages 314-319

  Van Etten, B ^a   De Vries, M R ^a   Van IJken, M G A ^a   Lans, T E ^a   Guetens, G ^c   Ambagtsheer, G ^a   Van Tiel, S T ^a   De Boeck, G ^c   De Bruijn, E A ^c   Eggermont, A M M ^a   Ten Hagen, T L M ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c NONE

Author keywords

Isolated hepatic perfusion; Liver metastases; Melphalan; Microvessel density; TNF

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DRUG TISSUE LEVEL; GROWTH RATE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER METASTASIS; LIVER PERFUSION; MALE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SOFT TISSUE SARCOMA; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MELPHALAN; MICROCIRCULATION; OSTEOSARCOMA; RATS; RATS, INBRED BN; SARCOMA; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037468140     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600707     Document Type: Article

References (25)

1. Alexander HR, Brown CK, Bartlett DL, Libutti SK, Figg WD, Raje S, Turner E (1998a) Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumour necrosis factor-independent mechanisms. Clin Cancer Res 4: 2357-2362.
2. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC (2000) A phase I-II study of isolated hepatic perfusion using melphalan with or without tumour necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6: 3062-3070.
3. Alexander HRJ, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA (1998b) Isolated hepatic perfusion with tumour necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16: 1479-1489.
4. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR (2001) Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129: 176-187.
5. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23: 755-761.
6. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82: 1000-1003.
7. Eggermont AM, Schraffordt KH, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996a) Isolated limb perfusion with tumour necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224: 756-764.
8. Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ (1996b) Isolated limb perfusion with high-dose tumour necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665.
9. Hoekstra HJ, Schraffordt KH, Molenaar WM, Oldhoff J (1987) Results of isolated regional perfusion in the treatment of malignant soft tissue tumours of the extremities. Cancer 60: 1703-1707.
10. Lejeune FJ, Lienard D, el Douaihy M, Seyedi JV, Ewalenko P (1989) Results of 206 isolated limb perfusions for malignant melanoma. Eur J Surg Oncol 15: 510-519.
11. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60.
12. Lindner P, Fjalling M, Hafstrom L, Kierulff-Nielsen H, Mattsson J, Schersten T, Rizell M, Naredi P (1999) Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 25: 179-185.
13. McBride CM (1974) Sarcomas of the limbs. Results of adjuvant chemotherapy using isolation perfusion. Arch Surg 109: 304-308.
14. Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, de Waal RM, Ruiter DJ (1996) Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 74: 1908-1915.
15. Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS (1997) Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumour necrosis factor. Ann Surg Oncol 4: 64-69.
16. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumour vasculature induced by TNF-α and IFN-gamma. Nat Med 4: 408-414.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
18. ten Hagen TL, Eggermont AM, Lejeune FJ (2001) TNF-α is here to stay-revisited. Trends Immunol 22: 127-129.
19. Thompson JF, Gianoutsos MP (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16: 227-233.
20. Tjaden UR, de Bruijn EA (1990) Chromatographic analysis of anticancer drugs. J Chromatogr 531: 235-294.
21. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer, 77: 1-10.
22. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de velde CJ (2000) Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 82: 1539-1546.
23. van IJken MG, van Etten B, de Wilt JH, van Tiel ST, ten Hagen TL, Eggermont AM (2000) Tumour necrosis factor-alpha augments tumour effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 23: 449-455.
24. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL (2000) TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82: 973-980.
25. van der Veen AH, Seynhaeve AL, Breurs J, Nooijen PT, Marquet RL, Eggermont AM (1999) In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. Br J Cancer 79: 433-439.